SEC Filing Summary: Hillstream BioPharma, Inc. (HILS)
Business Context and Reporting Period
This Form 8-K was filed by Hillstream BioPharma, Inc. on July 12, 2023. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, NJ. The filing reports a corporate governance event regarding the appointment of a new independent registered public accounting firm for the fiscal year ending December 31, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in the registrant's certifying accountant and does not contain financial performance data.
Material Changes
The primary material change reported is the replacement of the Company's independent registered public accounting firm:
- Outgoing Firm: Mayer Hoffman McCann P.C.
- Incoming Firm: Rosenberg Rich Baker Berman P.A. ("RRBB").
- Effective Date: July 12, 2023.
- Scope: RRBB is appointed for the fiscal year ending December 31, 2023.
The Company confirmed that during the two most recent fiscal years and the subsequent period through the appointment, it did not consult with RRBB regarding any matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies related to the accounting firm change were disclosed beyond the standard regulatory notification.
Investor Verification Checklist
- Verify the rationale for replacing Mayer Hoffman McCann P.C. with Rosenberg Rich Baker Berman P.A. in subsequent filings or press releases.
- Confirm that no disagreements existed with the former accountant regarding accounting principles or financial statement disclosures.
- Monitor upcoming financial reports to ensure the new auditor's review of the fiscal year 2023 financials proceeds without qualification.